CliffBio
small molecule

BANZEL

RUFINAMIDE

Loss of exclusivity—loss of exclusivity
CompanyEisai →See this company's full patent-cliff portfolio

Drug detail

Brand nameBANZEL
Active ingredientRUFINAMIDE
Strength40MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2011
Marketing statusRX

More from Eisai

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.